Pediatrics

A new study with infants reveals that those from vegetarian households follow growth trajectories nearly identical to their omnivorous peers by the age of 2.

Researchers found that 58% of infants with atopic dermatitis achieved a 75% improvement in EASI-75 at week 4 with once-daily roflumilast cream 0.05%.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

Results from the SPACE clinical trial showed fremanezumab reduced monthly migraine days versus placebo in children and adolescents with episodic migraine.

Your daily dose of the clinical news you may have missed.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.

CDC officials say the shift reflects evidence review and informed consent, as public health groups warn of potential downstream effects.

The inquiry follows internal requests for closer review of trial findings and real-world evidence; regulators have not yet indicated any planned actions.

Chari A. Cohen, DrPH, MPH, underscored the importance of trust, open dialogue, and evidence-based information.

Amid controversy, ACIP voted today to end the universal hepatitis B birth dose for infants of HBsAg-negative mothers, shifting to clinician-guided individual decision-making.

Adolescents acquiring smartphones at 12 showed increased risk for depression, obesity and sleep disturbances, according to a study of more than 10,000 youths.

Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.

A 2-fold rise in pediatric hypertension over 2 decades and new long-term imaging data signal a need to rethink how early clinicians act on elevated BP.

FDA reviews roflumilast cream for young children with plaque psoriasis, potentially offering a first-of-its-kind topical treatment option.

ACAAI 2025. Phase 3 data show tapinarof cream provides early, sustained improvement and good tolerability in children aged ≥2 years with atopic dermatitis.

Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Nonstimulant medications play a crucial role in ADHD treatment, offering effective alternatives for patients intolerant to stimulants or at risk of misuse.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

The FDA has initiated approval of leucovorin calcium tablets for children with cerebral folate deficiency, which can manifest with autistic features. What is it?